ESTRO 2025 - Abstract Book

S711

Clinical - CNS

ESTRO 2025

Conclusion: One-third of VS patients treated with SRS report worsened vestibular symptoms at 6 months. Vestibular system Dmean and Dmax are strongly associated with symptom worsening and, to some extent, with worsened measured vestibular function, suggesting that dose reductions to vestibular structures may help mitigate these outcomes without sacrificing PTV or cochlear protection

Keywords: Schwannoma SRS, Vestibular Toxicity, Dose Relation

2993

Mini-Oral Recurrence pattern analysis following glioblastoma radiotherapy with reduced CTV margins Alexander Nitschmann 1 , Sebastian Maier 1 , Diana-Coralia Dehelean 1 , Stephan Schönecker 1 , Sebastian N. Marschner 1,2 , Stefanie Corradini 1 , Claus Belka 1,2,3 , Maximilian Niyazi 4,1,5 , Daniel F. Fleischmann 1,2,6 1 Department of Radiation Oncology, LMU University Hospital, LMU Munich, Munich, Germany. 2 German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and LMU University Hospital, Munich, Germany. 3 Bavarian Cancer Research Center, (BZKF), Munich, Germany. 4 Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany. 5 German Cancer Consortium (DKTK), partner site Tübingen, a